Seer Inc. (NASDAQ: SEER) announced that its board of directors unanimously rejected a revised unsolicited acquisition proposal from Bradley L. Radoff and Michael Torok, together with certain affiliates known as the Radoff-JEC Group. The proposal offered $2.35 per share in cash plus a contingent value right for all outstanding Class A common stock.

The board determined the proposal significantly undervalues the proteomics company and is not in stockholders' best interests. Lead Independent Director Nicolas Roelofs stated the proposal implies an equity value materially below Seer's current cash, cash equivalents and investments, and fails to reflect the value of the company's platform and growth prospects.

Seer develops deep proteomics technology through its Proteograph Product Suite. The company reports growth in customer adoption and was recently selected for Singapore's SGK100 population-scale study. More than 80 peer-reviewed publications have featured Seer's technology, and the company holds 240 issued patents and patent applications worldwide, including 82 issued patents.

The board's Corporate Governance and Nominating Committee will review director nominees proposed by the Radoff-JEC Group according to company bylaws. The board will present its formal recommendation regarding these nominees in the definitive proxy statement for the 2026 Annual Meeting of Stockholders, whose date has not been announced.

Perella Weinberg Partners serves as Seer's financial advisor, while Wilson Sonsini Goodrich & Rosati provides legal counsel. The company stated stockholders do not need to take any action currently.